Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4615 News 


«12...4344454647484950515253...5758»
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio, Rituxan (rituximab) / Roche, Biogen
    Review, Journal:  Immunotherapy in myasthenia gravis in the era of biologics. (Pubmed Central) -  Jan 30, 2020   
    Belimumab, an antibody against the B cell trophic factor BAFF, was ineffective in phase III trials, and efgartigimod, which depletes antibodies, was effective in a phase II study...Checkpoint inhibitors can trigger MG in some patients, necessitating early intervention. Increased availability of new biologics provides targeted immunotherapies and the opportunities to develop more specific therapies.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Compendium of current complement therapeutics. (Pubmed Central) -  Jan 22, 2020   
    The driving role of complement in a single disease, paroxysmal nocturnal hemoglobinuria (PNH), provoked the development and eventual FDA (US Food and Drug Administration) approval of eculizumab (Soliris™), an anti-C5 antibody, for therapy...In this article, we do not set out to provide a text-heavy review of complement therapeutics but instead will simply highlight the targets, modalities and current status of the plethora of drugs approved or in clinical development. With such a fast-moving drug development landscape, such a compendium will inevitably become out-dated; however, we provide a snapshot of the current field and illustrate the increased choice that clinicians might enjoy in the future in selecting the best drug for their application, decisions based not only on efficacy but also cost, mechanistic target, modality and route of delivery.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Survey to assess variability in management of myasthenic crisis among neurologists () -  Jan 21, 2020 - Abstract #AAN2020AAN_2424;    
    Our survey indicates that there is considerable variability in the acute treatment of myasthenic crisis, and escalated therapy continues into the post-discharge recovery period. We intend to collate data from a much larger community of clinicians and have this available for presentation at the annual meeting.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Effect of Complement Inhibition on Lymphocytes in Treatment Refractory Myasthenia Gravis Patients () -  Jan 21, 2020 - Abstract #AAN2020AAN_2373;    
    Immunologically, eculizumab increased the frequency of selected CD8 T cells subsets and unbiased cluster analysis revealed that this increase stems from a rise in naïve and terminal effector CD8 T cells. Ongoing analyses will focus on less common immune subsets and qualitative immune signature changes in patients with a reduced clinical response to complement inhibition.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    The impact of relapses on quality of life in patients with neuromyelitis optica spectrum disorder: data from the phase 3 PREVENT study () -  Jan 21, 2020 - Abstract #AAN2020AAN_1562;    
    PREVENT was a randomized, double-blind study of eculizumab in patients with aquaporin-4 immunoglobulin-G positive NMOSD, which showed a 94% reduction in the risk of adjudicated relapse versus placebo and also included survey measurements of quality of life... This analysis suggests that relapses in patients with NMOSD are associated with a significant reduction in certain aspects of quality of life beyond the immediate relapse period.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Darzalex IV (daratumumab) / J&J, Soliris (eculizumab) / Alexion Pharma
    Daratumumab as First Line Therapy in a POEMS Syndrome Patient Demonstrating Atypical Features () -  Jan 21, 2020 - Abstract #AAN2020AAN_1106;    
    Our use of daratumumab contrasts its success as salvage-therapy in a prior case. In addition, our patient developed liver dysfunction and abnormal blood counts either due to progression of POEMS or daratumumab usage, neither of which are reported in literature.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder () -  Jan 21, 2020 - Abstract #AAN2020AAN_310;    
    P3
    In this long-term analysis, eculizumab was well tolerated and reported AEs were consistent with its established safety profile in other indications. The percentage of relapse-free patients remained high (~94%) through 192 weeks.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal, HEOR:  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. (Pubmed Central) -  Jan 1, 2020   
    This outcome is of great importance for the choice of therapeutic options in patients with refractory GMG. Eculizumab generates improvements in the perception of patients' quality of life compared to placebo, making it a relevant therapeutic option in the management of refractory GMG.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. (Pubmed Central) -  Jan 1, 2020   
    Deaths were more frequent in adult (4.7% and 9.9% of ever- and never-treated patients) compared with pediatric patients (1.8% of ever-treated patients; no deaths in never-treated patients).Three meningococcal infections were reported in ever-treated patients; 1 infection led to a fatal outcome. In this large observational dataset covering 5 years of registry enrollment, no new safety concerns were identified for adult or pediatric eculizumab-treated patients with aHUS, confirming a positive benefit-risk profile in a real-world setting.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS. (Pubmed Central) -  Jan 1, 2020   
    In this large observational dataset covering 5 years of registry enrollment, no new safety concerns were identified for adult or pediatric eculizumab-treated patients with aHUS, confirming a positive benefit-risk profile in a real-world setting. No abstract available
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Kidney Transplantation in C3 Glomerulopathy: A Case Series. (Pubmed Central) -  Dec 28, 2019   
    In a case series of C3G transplant recipients, the proportion of disease recurrence was high in both C3GN and DDD, although graft loss appeared to occur more frequently in DDD. In a small subset of study patients, eculizumab therapy was not consistently followed by salutary outcomes.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal, Adverse events:  Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis. (Pubmed Central) -  Dec 26, 2019   
    Presentation of obstetric-aHUS is preceded by various precipitating factors, suggesting pregnancy complications, and not the pregnancy per se, often induce aHUS in women with a genetic predisposition to its development. A delay in the correct diagnosis and initiation of the most effective treatment can have serious consequences, reinforcing the need to raise awareness of obstetric-aHUS.
  • ||||||||||  tacrolimus / Generic mfg., Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience. (Pubmed Central) -  Dec 26, 2019   
    A delay in the correct diagnosis and initiation of the most effective treatment can have serious consequences, reinforcing the need to raise awareness of obstetric-aHUS. Patients with aHUS may be transplanted successfully with eculizumab with good allograft outcomes.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
    Journal:  Rituximab to Abbreviate Plasma Exchange in Anti-CFH (Complement Factor H) Antibody Mediated Atypical HUS. (Pubmed Central) -  Dec 23, 2019   
    Rituximab might be a useful alternative in inducing haematological remission in children with poor or no response to plasma therapy. This abbreviates the duration of plasma exchange, which not only avoids complications due to prolonged plasma therapy but also helps reducing the cost of therapy.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. (Pubmed Central) -  Dec 21, 2019   
    Recent literature on aHUS shows that intestinal complications are more common than described before, particularly for patients with anti-H factor antibodies. Moreover, we found some report of patient with both aHUS and IBD, who benefit from anti-C5 antibodies injection (Eculizumab).
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Complement Blockade for TA-TMA: Lessons Learned from Large Pediatric Cohort Treated with Eculizumab (World Center Marriott - Palms & Cypress Foyers) -  Dec 18, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_769;    
    The best CystC GFR recovery in survivors was a median 20% lower (IQR 7.3-40.3%) than their pre-HSCT CystC GFR. Conclusion Complement blockade with eculizumab is an effective therapeutic strategy for high risk TA-TMA, but some patients with severe disease lack a complete response, prompting us to propose early intervention strategies and search for additional targetable endothelial injury pathways.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls - A Critical Review Article. (Pubmed Central) -  Dec 10, 2019   
    The recent advent of the therapeutic monoclonal antibody Eculizumab has dramatically improved both the quality of life and the life expectancy of the affected patients, further increasing the importance of an accurate FCM detection and monitoring of the clones. The technical features of the FCM diagnostic workup and the many critical aspects of the analytical process are discussed here.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann's disease. (Pubmed Central) -  Dec 8, 2019   
    The observation that complement system is overly active in CHAPLE disease introduced a novel concept into the management of PLE; anti-complement therapy. While CD55 deficiency constitutes a treatable subgroup in the larger pool of patients with isolated PIL, the etiology remains to be identified in the remaining patients with intact CD55.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy (World Center Marriott - Palms: Sabal) -  Dec 8, 2019 - Abstract #TCTASTCTCIBMTR2020TCT_586;    
    Conclusion Our observations suggest co-activation of both interferon and complement pathways as a potential culprit in the evolution of thrombotic microangiopathy in patients with inflammatory disorders like HLH and may offer novel therapeutic approaches for these critically ill patients. TMA should be considered in children with HLH and multi-organ failure, as early institution of a brief course of complement blocking therapy in addition to HLH targeted therapy may improve clinical outcomes in these patients (Figure 3).
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Eculizumab therapy in paroxysmal nocturnal haemoglobinuria patient undergoing aortic valve surgery. (Pubmed Central) -  Dec 6, 2019   
    We report the successful management of a 69-year-old man undergoing aortic valve replacement with standard heparin-protamine protocol by using eculizumab, a monoclonal antibody of complement factor C5. The surgery was performed without triggering a haemolytic crisis, and the patient was discharged from the hospital without major complications.